This article is more than 5 years old. Information may no longer be current.
Top updates in reproduction/androgen disorders
Click Here to Manage Email Alerts
Here’s a look at the most popular reproduction/androgen disorder news in Endocrine Today from the last month. Readers were interested in FDA approval for a bioidentical hormone therapy, hypoactive sexual desire disorder and the effects of menopause on sleep.
FDA approves bioidentical hormone therapy for menopausal hot flashes
The FDA has approved the first bioidentical hormone therapy combination of estradiol and progesterone for moderate to severe vasomotor symptoms associated with menopause.
Menopause brings additional complications to sleep disturbances
Women’s sleep in midlife can be influenced by general aging and menopause — often at the same time — but health care providers can learn to spot differences to more effectively treat patients. Sleep disturbances are common for aging men and women, but hormonal changes brought on by menopause are unique and can require different, or additional, forms of treatment.
Modern aphrodisiacs address hypoactive sexual desire disorder
Hypoactive sexual desire disorder is the most common sexual dysfunction in women, with an estimated prevalence rate of 10% in the United States. Defined as a persistent or recurrent absence or deficiency of sexual desire, the condition known as HSDD is characterized by a lack of sexual appetite, erotic thoughts/fantasies or desire to engage in sexual activity. For affected women, this lack of desire is often a source of distress, frustration and grief.
Vitamin D deficiency may increase breast cancer risk in postmenopausal women
Postmenopausal women with recently diagnosed breast cancer had a higher risk for developing vitamin D deficiency vs. similar women without the disease, with obesity influencing vitamin D status.
Prenatal androgen exposure associated with male psychosexuality in disorders of sex development
Exposure to prenatal androgens, and not virilization of external genitalia, is associated with many psychosexual outcomes, including self-reported gender identity and sexual orientation, according to study findings published in The Journal of Clinical Endocrinology & Metabolism.